1. Meet the JAKs

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Cytokine Signaling Plays a Key Role in the Pathogenesis of Rheumatoid Arthritis (RA)

4. Janus Kinases (JAKs)

5. JAK Inhibitor Animation

6. Targeting JAK Inhibitors vs Traditional Biologic Therapies

7. JAK Inhibitors Approved by EMA

8. Signaling Pathways of Different JAKs

9. JAK Inhibitors in Latest Stage of Development in RA

10. Selective Targeting of Different JAKs

11. Targeting Different JAKs: Tofacitinib and Baricitinib

12. Tofacitinib in Previously Treated Patients

13. Tofacitinib in Patients With No Prior MTX Treatment

14. Select Phase 3 Trials of Baricitinib in RA

15. Targeting Different JAKs: Upadacitinib and Filgotinib

16. Upadacitinib in Patients Treated Previously With bDMARD or csDMARD: Phase 3 Studies

17. Upadacitinib in Patients With No Prior MTX: Phase 3 Study SELECT-EARLY

18. Safety of Upadacitinib: SELECT-EARLY

19. Early Use of JAK inhibitors: Expert Perspective

20. Filgotinib in Patients With Prior bDMARDs: Phase 3 Study

21. Targeting Different JAKs: Peficitinib

22. Phase 3 Trials of Peficitinib in RA

23. Selective JAK Inhibition and Clinical Efficacy

24. Safety of JAK Inhibitors

25. Safety of JAK Inhibitors (cont)

26. JAK Inhibitors in RA: Addressing Unmet Needs

27. JAK Inhibitors in RA: Addressing Unmet Needs (cont)

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)